Management of Suspected CNS Tuberculosis

Diagnostic Actions

The American Thoracic Society/CDC/IDSA guidelines recommend collecting at least three sputum specimens (or cerebrospinal fluid if CNS involvement suspected) for AFB smear microscopy, mycobacterial culture, and drug susceptibility testing before starting treatment, but do not delay treatment initiation 4, 5
Obtain rapid molecular testing (Xpert MTB/RIF or TB-LAMP) on initial specimens to detect rifampicin resistance and confirm TB diagnosis rapidly 4, 5
Perform chest radiography and brain imaging (MRI preferred for CNS TB) to assess disease extent and identify complications 4
Test for HIV infection, as this fundamentally alters treatment approach and may explain immune dysregulation 4, 5

The American Thoracic Society/CDC/IDSA guidelines explicitly state that an expanded regimen is indicated for patients with CNS involvement, as treatment with an inadequate regimen could have severe consequences 1, 2, 3, 6
Initiate daily therapy with isoniazid, rifampin, pyrazinamide, and ethambutol PLUS a later-generation fluoroquinolone and an injectable agent 1, 2, 3
All drugs must be administered using directly observed therapy (DOT) 1, 2, 3
Continue the expanded regimen until drug susceptibility results are available, then adjust accordingly 1, 2, 3

Obtain baseline hepatic enzymes, serum creatinine, complete blood count, and HIV testing 4, 7
Perform baseline visual acuity and color discrimination testing before ethambutol initiation 4
Check renal function before streptomycin or ethambutol use; if renal failure present, avoid these drugs or monitor serum concentrations with substantially reduced dosages 8
Monitor liver function tests weekly for two weeks, then every 2-4 weeks during the first two months, especially given the multi-drug regimen 8, 7

CNS tuberculosis typically requires extended treatment duration beyond the standard 6 months, often 9-12 months, though guidelines do not provide definitive duration 9
The decision should account for disease severity, clinical response, and culture conversion 9
Conduct monthly clinical assessments for treatment response and adverse effects 5, 7
Obtain monthly sputum or CSF cultures until two consecutive specimens are negative 4, 5

Do not wait for culture confirmation or drug susceptibility results before starting the expanded regimen in suspected CNS TB, as mortality increases with treatment delay 4, 7
Never add a single drug to a failing regimen, as this leads to acquired resistance 10, 5
Always add at least two, preferably three, new drugs to which susceptibility can be inferred 10
Monitor hemoglobin closely and discontinue the offending drug if hemolytic anemia develops, substituting with an alternative agent in consultation with TB specialists 1, 2